400-920-2911 sales@csnpharm.cn
Aurora Kinase
货号 | 产品名 | CAS号 | 信息 |
---|---|---|---|
CSN12727 | ZM-447439 | 331771-20-1 | ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM, 130 nM respectively, > 8 fold selectivity than Aurora C, MEK1, Src. |
CSN26598 | Tripolin A | 1148118-92-6 | Tripolin A ((E)-Tripolin A) is a specific non-ATP competitive Aurora A kinase inhibitor, with IC50 values of 1.5 μM and 7 μM for Aurora A and Aurora B, respectively[1]. |
CSN12326 | Tozasertib | 639089-54-6 | Tozasertib is the inhibitor of Aurora-A, -B, -C kinases with Ki values of 0.6, 18, 4.6 nM respectively. |
CSN23149 | TC-A 2317 hydrochloride | 1245907-03-2 | TC-A2317 HCl is an Aurora kinase A inhibitor. |
CSN16128 | TAK-901 | 934541-31-8 | TAK-901 is an inhibitor of Aurora A/B with IC50 of 21 nM/15 nM. |
CSN20031 | (Z)-Orantinib | 210644-62-5 | SU6668 is a cell-permeable indolinone compound that acts as a potent ATP-competitive inhibitor against RTKs (receptor tyrosine kinases) Kit, PDGFRβ, VEGFR2 (Flk-1/KDR), FGFR1 activity in vitro (IC50 = 0.01, 0.1, 3.9, and 3.8 µM, respectively) and PDGF/VEGF/bFGF-mediated angiogenesis and tumor development. Although initially characterized as an RTK inhibitor, SU6668 is now also known to target ser/thr kinases Aurora A, Aurora B, TBK1 (NAK/T2K), and AMPK (IC50 = 0.85, 0.047, 1.4, and 1.8 µM, respectively), as well as non-receptor TKs Lyn and Yes (IC50 = 4.3 and 5.8 µM, respectively). |
CSN27599 | SP-96 | 2682114-54-9 | SP-96 is a highly selective and non-ATP-competitive Aurora A/B inhibitor with IC50 values of 0.316nM 18.975 nM for Aurora A and Aurora B, respectively. |
CSN18798 | SNS-314 mesylate | 1146618-41-8 | SNS-314 is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. |
CSN13118 | SCH-1473759 | 1094069-99-4 | SCH-1473759 is a sub-nanomolar Aurora A/B inhibitor with IC50 of 4 nM and 13 nM, respectively. |
CSN17462 | SCH-1473759 hydrochloride | 1094067-13-6 | SCH-1473759 HCl is a sub-nanomolar Aurora A/B inhibitor with IC50 of 4 nM and 13 nM, respectively. |
CSN15807 | Reversine | 656820-32-5 | Reversine, a synthetic purine analogue(2,6-disubstituted purine), is a potent human A3 adenosine receptor antagonist with Ki of 0.66 μM, and a pan-aurora A/B/C kinase inhibitor with IC50 of 12 nM/13 nM/20 nM, respectively. |
CSN12811 | PHA-680632 | 398493-79-3 | PHA-680632 is potent inhibitor of Aurora A, B and C with IC50 of 27 nM, 135 nM and 120 nM, respectively. |
CSN18615 | PF-03814735 | 942487-16-3 | PF-03814735 is a potent, orally bioavailable, reversible small-molecule Aurora kinase inhibitor with IC50 of 0.8, 5, 10 and 22 nM for Aurora A, Aurora B, Flt 1 and FAk, respectively. |
CSN25344 | NU6140 | 444723-13-1 | NU6140 is a selective CDK2 inhibitor with IC50 value of 0.94μM, as well as potently inhibits Aurora kinase A/B with IC50 values of 0.035 and 0.067μM, respectively. |
CSN12363 | MLN8054 | 869363-13-3 | MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM and exhibits more than 40-fold selective for Aurora A than Aurora B. |
CSN16817 | MK-8745 | 885325-71-3 | MK-8745 is a potent and selective Aurora an inhibitor with IC50 of 0.6 nM, more than 450-fold selectivity for Aurora A over Aurora B. |
CSN17389 | MK-5108 | 1010085-13-8 | MK-5108 is a potent and highly selective Aurora inhibitor with IC50 of 0.064, 14 and 12 nM for Aurora A, B and C. |
CSN13761 | Hesperadin | 422513-13-1 | Hesperadin is a potent and ATP-competitive inhibitor of Aurora B kinase with IC50 of 250 nM. |
CSN12395 | GSK-1070916 | 942918-07-2 | GSK1070916 is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM and displays > 100-fold selectivity against the closely related Aurora A-TPX2 complex (IC50=490 nM). |
CSN24802 | BPR1K871 | 2443767-35-7 | DBPR114 is a potent multi-kinase inhibitor with potent activities against more than 57 oncogenic kinases, including Aurora-A, FLT3, CSF1R, MET, etc. DBPR114 exhibited favorable PK profiles: a long half-life (t1/2 = 23.5 h), moderate clearance and high volume of distribution. Also DBPR114 can effectively inhibit the growth of human acute myeloid leukemia MOLM-13 and MV4-11, MIA PaCa-2, Hep3B, MKN45, Colo205, and NTUB1 solid tumor xenografts in vivo without causing significant body weight loss. |
CSN12423 | Danusertib | 827318-97-8 | Danusertib is a pyrrolo-pyrazole and small molecule Aurora kinases inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively. It is modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. |
CSN17118 | CYC-116 | 693228-63-6 | CYC116 is a potent inhibitor of Aurora with Ki of 8.0 nM/9.2 nM for Aurora A/B. |
CSN16269 | CTX-0294885 | 1439934-41-4 | CTX-0294885 is a bisanilino pyrimidine and exhibits inhibitory activity against a broad range of kinases in vitro, further developed into a Sepharose-supported kinase capture reagent. CTX-0294885 is a broad spectrum kinase inhibitor that inhibited FAK, FLT3, JAK2, JAK3, Src, Aurora kinase A, and VEGF receptor 3 (IC50s = 4, 1, 3, 28, 2, 18, and 3 nM, respectively) in an initial screen. |
CSN50650 | CD532 | 1639009-81-6 | CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer. |
CSN27200 | CCT241736 | 1402709-93-6 | CCT241736 is a dual FLT3/Aurora kinase A/B inhibitor with IC50 values of 0.035μM, 0.015μM and 0.1μM, respectively. |
CSN17149 | CCT 137690 | 1095382-05-0 | CCT137690 is a potent inhibitor of Aurora kinases (IC50 values are 0.015, 0.019 and 0.025 μM at Aurora A, Aurora C and Aurora B respectively). |
CSN16415 | CCT129202 | 942947-93-5 | CCT129202 is a Aurora kinase inhibitor with IC50 of 0.042 ± 0.022, 0.198 ± 0.05, and 0.227 ± 0.064 μM for Aurora A, Aurora B, and Aurora C, respectively. |
CSN16205 | BI-847325 | 1207293-36-4 | BI-847325 is a selective and orally bioavailable dual MEK/Aurora kinase inhibitor with IC50 of 3 nM (Xenopus laevis Aurora B), 25 nM (human Aurora A), 15 nM (human Aurora C), 25 nM (human MEK1), and 4 nM (human MEK2) respectively. |
CSN17268 | Barasertib-HQPA | 722544-51-6 | AZD1152-HQPA is the active metabolite of AZD-1152 and a highly selective Aurora B inhibitor with IC50 of 0.37 nM, ~100 fold selective for Aurora B over Aurora A. |
CSN23770 | Aurora kinase inhibitor-3 | 879127-16-9 | Aurora kinase inhibitor III is a potent ATP-competitive aurora related kinase (also designated ARK) inhibitor with IC50 value of 42 nM for Aurora A kinase. |
CSN12380 | TCS7010 | 1158838-45-9 | Aurora an inhibitor I is a potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold selective for Aurora A than Aurora B. |
CSN12715 | AT9283 | 896466-04-9 | AT9283 is a multi-targeted inhibitor with IC50s of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl (T315I), JAK2 and JAK3, Aurora A and Aurora B, respectively. |
CSN26521 | (Z)-SKI V | 927429-51-4 | and a Kd of 3.06 μM. (Z)-SKI V inhibits Aurora A with an IC50 of 1.34 μM. (Z)-SKI V, a benzofuran derivative, has extensive cytotoxic effects on cancer cell lines[1]. |
CSN16543 | AMG 900 | 945595-80-2 | AMG-900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM, and is > 10-fold selective for Aurora kinases than p38α, Tyk2, JNK2, Met and Tie2. |
CSN13457 | Alisertib | 1028486-01-2 | Alisertib is a selective Aurora inhibitor with IC50 of 1.2 nM with > 200-fold higher selectivity for Aurora A than Aurora B. |
CSN103809 | 1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea (S)-2-hydroxypropanoate | 896466-76-5 |